Study shows that anti-PTM antibodies are often present in autoimmune mediated liver disease

FHS
July 31, 2023
11:28 am

A recent study published in Frontiers in Medicine described anti-post-translational modification (PTM) antibodies in patients with autoimmune-mediated and cholestatic liver diseases (AILD).

Bristol Myers Squibb acquires RayzeBio for $4.1bn

Share this article Through the RayzeBio acquisition, BMS will gain access to an RPT manufacturing facility. Credit: JHVEPhoto / Shutterstock.com. Bristol Myers Squibb (BMS) has

February 27, 2024

Tulane study finds potential treatment for eosinophilic esophagitis

A new study from Tulane University has identified a new treatment for a chronic immune system disease that can prevent children from eating.

July 31, 2023

Risk Adjusted Net Present Value: What is the current valuation of AbbVie’s Navitoclax dihydrochloride

The revenue for Navitoclax dihydrochloride is expected to reach an annual total of $315 mn by 2034 in the US based off GlobalDatas Expiry Model.

September 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.